Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Sandrine Faivre, Armando Santoro, Robin K Kelley, Ed Gane, Charlotte E Costentin, Ivelina Gueorguieva, Claire Smith, Ann Cleverly, Michael M Lahn, Eric Raymond, Karim A Benhadji, Gianluigi Giannelli

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND AIMS: We assessed the activity of galunisertib, a small molecule inhibitor of the transforming growth factor beta (TGF-β1) receptor I, in second-line patients with hepatocellular carcinoma (HCC) in two cohorts of baseline serum alpha fetoprotein (AFP).METHODS: Patients with advanced HCC who progressed on or were ineligible to receive sorafenib, Child-Pugh A/B7 and ECOG PS ≤1 were enrolled into Part A (AFP ≥ 1.5× ULN) or Part B (AFP <1.5× ULN). Patients were treated with 80 or 150 mg galunisertib BID for 14 days per 28-day cycle. Endpoints were time-to-progression (TTP) and changes in circulating AFP and TGF-β1 levels, as well as safety, pharmacokinetics, progression-free survival and overall survival (OS).RESULTS: Patients (n = 149) were enrolled with median age 65 years. Median TTP was 2.7 months (95% CI: 1.5-2.9) in Part A (n = 109) and 4.2 months (95% CI: 1.7-5.5) in Part B (n = 40). Median OS was 7.3 months (95% CI: 4.9-10.5) in Part A and 16.8 months (95% CI: 10.5-24.4) in Part B. OS was longer in AFP responders (>20% decrease from baseline, Part A) compared to non-responders (21.5 months vs 6.8 months). OS was longer in TGF-β1 responders (>20% decrease from baseline, all patients) compared to non-responders. The most common Grade 3/4 treatment-related adverse events were neutropenia (n = 4) and fatigue, anaemia, increased bilirubin, hypoalbuminemia and embolism (each, n = 2).CONCLUSIONS: Galunisertib treatment had a manageable safety profile in patients with HCC. Lower baseline AFP and a response in AFP or TGF-β1 levels (vs no response) correlated with longer survival.TRIAL REGISTRATION NUMBER: NCT01246986 at ClinicalTrials.gov.
Original languageEnglish
Pages (from-to)1468-1477
Number of pages10
JournalLiver International
Volume39
Issue number8
DOIs
Publication statusPublished - Aug 2019

Fingerprint Dive into the research topics of 'Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Faivre, S., Santoro, A., Kelley, R. K., Gane, E., Costentin, C. E., Gueorguieva, I., Smith, C., Cleverly, A., Lahn, M. M., Raymond, E., Benhadji, K. A., & Giannelli, G. (2019). Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International, 39(8), 1468-1477. https://doi.org/10.1111/liv.14113